INVESTOR ALERT: Kirby McInerney LLP Announces Investigation on Behalf of Myriad Genetics, Inc. (MYGN) Investors
March 16 2018 - 4:56PM
Business Wire
The law firm of Kirby McInerney LLP announced today an
investigation on behalf of Myriad Genetics, Inc. (“Myriad” or the
“Company”) (NASDAQ:MYGN) investors concerning officers’ possible
violations of federal securities laws.
Myriad is a molecular diagnostic company. On March 12, 2018,
Myriad disclosed that it had received a subpoena from the
Department of Health and Human Services, Office of Inspector
General, in connection with an investigation into possible false or
otherwise improper claims submitted for payment under Medicare and
Medicaid. The subpoena requested that the Company produce documents
relating primarily to the Company's billing to government-funded
healthcare programs for the Company's hereditary cancer
testing.
On this news, Myriad’s share price fell from $33.01 to close at
$29.01 on March 13, 2018 (a decline of $4.01).
If you purchased or otherwise acquired Myriad securities, have
information or would like to learn more about these claims, please
contact Thomas W. Elrod of Kirby McInerney LLP at 212-371-6600, by
email at telrod@kmllp.com, or by
filling out this contact form to discuss your rights or interests
with respect to these matters without any cost to you.
Kirby McInerney LLP is a New York-based plaintiffs’ law firm
concentrating in securities, antitrust, whistleblower and consumer
litigation. The firm’s efforts on behalf of shareholders in
securities litigation have resulted in recoveries totaling billions
of dollars. Additional information about the firm can be found at
Kirby McInerney LLP’s website: http://www.kmllp.com.
This press release may be considered Attorney Advertising in
some jurisdictions under the applicable law and ethical rules.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20180316005858/en/
Kirby McInerney LLPThomas W. Elrod,
212-371-6600http://www.kmllp.comtelrod@kmllp.com
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Apr 2023 to Apr 2024